




I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature and Deposit: August 25, 2003


Nicholas J. Seay, Reg. No. 27,386

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alan D. Attie
Donald L. Gillian-Daniel
Paul W. Bates

Date: August 25, 2003

Serial No.: 09/620,820

Group Art Unit: 1636

Filed: July 21, 2000

Examiner: Celine X. Qian

Title: INHIBITION OF LIPOPROTEIN SECRETION

File No.: 960296.97290

AMENDMENT

RECEIVED

SEP 08 2003

Commissioner For Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TECH CENTER 1600/2900

Dear Sir:

In response to the Office Action dated March 25, 2003 in the file of the above-identified application, please amend that application as follows:

In the Claims:

Please amend Claims 1, 5 and 9 as follows and add the following new Claim 17.

1. (Currently Amended) A method for the lowering of serum cholesterol levels in a mammal comprising the steps of

making a genetic construct comprising (1) a protein coding sequence encoding for the expression of a fusion protein, the fusion protein including (a) a truncated form of a low density lipoprotein receptor which includes the domain providing the function of binding to low density lipoprotein but does not include the domain of the native protein associated with membrane binding or the domain associated with O-linked sugars, and (b) a localization domain which directs localization of the fusion protein to the interior of a cell in the mammal so that the fusion protein will become localized to the endoplasmic reticulum, and (2) a promoter effective in the cells of the mammal to express the protein coding sequence; and